Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy

Antonio Di Meglio, Julie Havas, Arnauld S Gbenou, Elise Martin, Mayssam El-Mouhebb, Barbara Pistilli, Gwenn Menvielle, Agnes Dumas, Sibille Everhard, Anne-Laure Martin, Paul H Cottu, Florence Lerebours, Charles Coutant, Anne Lesur, Olivier Tredan, Patrick Soulie, Laurence Vanlemmens, Florence Joly, Suzette Delaloge, Patricia A Ganz, Fabrice André, Ann H Partridge, Lee W Jones, Stefan Michiels, Ines Vaz-Luis, Antonio Di Meglio, Julie Havas, Arnauld S Gbenou, Elise Martin, Mayssam El-Mouhebb, Barbara Pistilli, Gwenn Menvielle, Agnes Dumas, Sibille Everhard, Anne-Laure Martin, Paul H Cottu, Florence Lerebours, Charles Coutant, Anne Lesur, Olivier Tredan, Patrick Soulie, Laurence Vanlemmens, Florence Joly, Suzette Delaloge, Patricia A Ganz, Fabrice André, Ann H Partridge, Lee W Jones, Stefan Michiels, Ines Vaz-Luis

Abstract

Purpose: We aimed to characterize long-term quality of life (QOL) trajectories among patients with breast cancer treated with adjuvant chemotherapy and to identify related patterns of health behaviors.

Methods: Female stage I-III breast cancer patients receiving chemotherapy in CANTO (CANcer TOxicity; ClinicalTrials.gov identifier: NCT01993498) were included. Trajectories of QOL (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 Summary Score) and associations with trajectory group membership were identified by iterative estimations of group-based trajectory models and multivariable multinomial logistic regression, respectively.

Results: Four trajectory groups were identified (N = 4,131): excellent (51.7%), very good (31.7%), deteriorating (10.0%), and poor (6.6%) QOL. The deteriorating trajectory group reported fairly good baseline QOL (mean [95% CI], 78.3/100 [76.2 to 80.5]), which significantly worsened at year-1 (58.1/100 [56.4 to 59.9]) and never recovered to pretreatment values through year-4 (61.1/100 [59.0 to 63.3]) postdiagnosis. Healthy behaviors were associated with better performing trajectory groups. Obesity (adjusted odds ratio [aOR] v lean, 1.51 [95% CI, 1.28 to 1.79]; P < .0001) and current smoking (aOR v never, 1.52 [95% CI, 1.27 to 1.82]; P < .0001) at diagnosis were associated with membership to the deteriorating group, which was also characterized by a higher prevalence of patients with excess body weight and insufficient physical activity through year-4 and by frequent exposure to tobacco smoking during chemotherapy. Additional factors associated with membership to the deteriorating group included younger age (aOR, 1-year decrement 1.01 [95% CI, 1.01 to 1.02]; P = .043), comorbidities (aOR v no, 1.22 [95% CI, 1.06 to 1.40]; P = .005), lower income (aOR v wealthier households, 1.21 [95% CI, 1.07 to 1.37]; P = .002), and endocrine therapy (aOR v no, 1.14 [95% CI, 1.01 to 1.30]; P = .047).

Conclusion: This latent-class analysis identified some patients with upfront poor QOL and a high-risk cluster with severe, persistent postchemotherapy QOL deterioration. Screening relevant patient-level characteristics may inform tailored interventions to mitigate the detrimental impact of chemotherapy and preserve QOL, including early addressal of behavioral concerns and provision of healthy lifestyle support programs.

Conflict of interest statement

Barbara Pistilli

Consulting or Advisory Role: Puma Biotechnology, Pierre Fabre, Novartis, Myriad Genetics, AstraZeneca, Daiichi Sankyo/UCB Japan

Research Funding: Pfizer (Inst), Puma Biotechnology (Inst), Merus (Inst), Daiichi-Sankyo (Inst)

Travel, Accommodations, Expenses: Pfizer, AstraZeneca, MSD Oncology, Novartis, Pierre Fabre

Paul H. Cottu

Honoraria: Pfizer, Novartis (Inst), Roche, NanoString Technologies (Inst), Lilly

Consulting or Advisory Role: Pfizer, Lilly

Research Funding: Pfizer (Inst)

Travel, Accommodations, Expenses: Roche, Pfizer

Florence Lerebours

Consulting or Advisory Role: AstraZeneca, Eisai, Lilly, Pierre Fabre, Roche, Pfizer, Novartis, Seattle Genetics

Travel, Accommodations, Expenses: Novartis, Pfizer, Roche, Eisai, Mundipharma

Charles Coutant

Travel, Accommodations, Expenses: Roche, MSD, AstraZeneca, Pfizer, Seattle Genetics, Exact Sciences

Olivier Tredan

Consulting or Advisory Role: Roche, Pfizer, Lilly, AstraZeneca, MSD Oncology, Daiichi Sankyo Europe GmbH, Eisai Europe, Sandoz-Novartis, Seattle Genetics, Pierre Fabre, Gilead Sciences

Research Funding: Roche (Inst), Bristol Myers Squibb (Inst), MSD Oncology (Inst), AstraZeneca (Inst), Novartis (Inst), Bayer (Inst)

Travel, Accommodations, Expenses: Roche, Novartis, Pfizer, Lilly, AstraZeneca, MSD Oncology

Patrick Soulie

Travel, Accommodations, Expenses: Pfizer, PharmaMar, Ipsen

Florence Joly

Consulting or Advisory Role: AstraZeneca, Janssen, Ipsen, Pfizer, MSD Oncology, Bristol Myers Squibb, GlaxoSmithKline, Astellas Pharma, Clovis Oncology, Amgen, Seattle Genetics, Bayer

Travel, Accommodations, Expenses: Janssen, AstraZeneca, Ipsen, GlaxoSmithKline, BMS

Suzette Delaloge

Consulting or Advisory Role: AstraZeneca (Inst), Sanfi (Inst), Besins Healthcare (Inst), Rappta Therapeutics (Inst)

Research Funding: AstraZeneca (Inst), Pfizer (Inst), Roche/Genentech (Inst), Puma Biotechnology (Inst), Lilly (Inst), Novartis (Inst), Sanofi (Inst), Exact Sciences (Inst), Bristol Myers Squibb (Inst)

Travel, Accommodations, Expenses: Pfizer, AstraZeneca, Novartis (Inst)

Patricia A. Ganz

Leadership: Intrinsic LifeSciences (I)

Stock and Other Ownership Interests: Xenon Pharma (I), Intrinsic LifeSciences (I), Silarus Therapeutics (I), Teva, Novartis, Merck, Johnson & Johnson, Pfizer, GlaxoSmithKline, Abbott Laboratories

Consulting or Advisory Role: InformedDNA, Vifor Pharma (I), Ambys Medicines (I), Global Blood Therapeutics (I), GlaxoSmithKline (I), Ionis Pharmaceuticals (I), Akebia Therapeutics (I), Protagonist Therapeutics (I), Regeneron (I), Sierra Oncology (I), Rockwell Medical Technologies Inc (I), Astellas Pharma (I), Gossamer Bio (I), American Regent (I), Disc Medicine (I), Blue Note Therapeutics, Grail

Research Funding: Blue Note Therapeutics (Inst)

Patents, Royalties, Other Intellectual Property: related to iron metabolism and the anemia of chronic disease (I), Up-to-Date royalties for section editor on survivorship

Travel, Accommodations, Expenses: Intrinsic LifeSciences (I)

Fabrice André

Stock and Other Ownership Interests: Pegacsy

Research Funding: AstraZeneca (Inst), Novartis (Inst), Pfizer (Inst), Lilly (Inst), Roche (Inst), Daiichi (Inst)

Travel, Accommodations, Expenses: Novartis, Roche, GlaxoSmithKline, AstraZeneca

Ann H. Partridge

Patents, Royalties, Other Intellectual Property: I receive small royalty payments for coauthoring the breast cancer survivorship section of UpToDate

Open Payments Link: https://openpaymentsdata.cms.gov/physician/835197

Lee W. Jones

Stock and Other Ownership Interests: Pacylex

Stefan Michiels

Consulting or Advisory Role: IDDI, Sensorion, Biophytis, Servier, Yuhan, Amaris Consulting, Roche

Ines Vaz-Luis

Honoraria: AstraZeneca (Inst), Amgen (Inst), Pfizer (Inst)

No other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Trajectory groups according to best-fitting model (N = 4131). Solid lines represent the predicted trajectories and dashed lines represent the respective 95% CIs. The table below the figure displays the predicted C30 Summary Score values and respective 95% CIs by trajectory group. C30 Summary Scores were available for 3,816 patients at diagnosis, and then among 3,477 at year-1 follow-up; 3,102 at year-2 follow-up; and 2,241 patients at year-4 follow-up. Higher scores reflect better QOL. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; QOL, quality of life.
FIG 2.
FIG 2.
(A) Mean QOL scores by trajectory group and by time point: EORTC QLQ-C30 functions; (B) mean QOL scores by trajectory group and by time point: EORTC QLQ-C30 symptoms. Thresholds for clinical importance are defined by horizontal, dotted gray lines. Higher scores indicate greater functionality and symptomatology. Scores below and above the threshold indicate clinically important functional impairment and symptomatology, respectively (Giesinger JM, et al: J Clin Epidemiol 2020). Respective 95% CIs for the means are available in the Data Supplement. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; QOL, quality of life.

References

    1. Allemani C, Weir HK, Carreira H, et al. : Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385:977-1010, 2015
    1. Berry DA, Cronin KA, Plevritis SK, et al. : Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005
    1. DeSantis CE, Bray F, Ferlay J, et al. : International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 24:1495-1506, 2015
    1. Saadatmand S, Bretveld R, Siesling S, et al. : Influence of tumour stage at breast cancer detection on survival in modern times: Population based study in 173 797 patients. BMJ 351:h4901, 2015
    1. SEER Cancer Statistics Review 1975-2006-Previous Version—SEER Cancer Statistics.
    1. Sheng JY, Visvanathan K, Thorner E, et al. : Breast cancer survivorship care beyond local and systemic therapy. Breast 48:S103-S109, 2019
    1. Brauer ER, Ganz PA: Health burden in cancer survivors: Below the tip of the iceberg. Nat Rev Clin Oncol 16:467-468, 2019
    1. Howard-Anderson J, Ganz PA, Bower JE, et al. : Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: A systematic review. J Natl Cancer Inst 104:386-405, 2012
    1. Ahles TA, Saykin AJ, McDonald BC, et al. : Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: Impact of age and cognitive reserve. J Clin Oncol 28:4434-4440, 2010
    1. Bower JE, Ganz PA, Desmond KA, et al. : Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743-753, 2000
    1. Bandos H, Melnikow J, Rivera DR, et al. : Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG oncology/NSABP B-30. J Natl Cancer Inst 110:djx162, 2017
    1. Hassett MJ, O'Malley AJ, Pakes JR, et al. : Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117, 2006
    1. Dumas A, Vaz Luis I, Bovagnet T, et al. : Impact of breast cancer treatment on employment: Results of a multicenter prospective cohort study (CANTO). J Clin Oncol 38:734-743, 2020
    1. Andrykowski MA, Donovan KA, Laronga C, et al. : Prevalence, predictors, and characteristics of off-treatment fatigue in breast cancer survivors. Cancer 116:5740-5748, 2010
    1. Bower JE, Wiley J, Petersen L, et al. : Fatigue after breast cancer treatment: Biobehavioral predictors of fatigue trajectories. Heal Psychol 37:1025-1034, 2018
    1. Bower JE, Ganz PA, Desmond KA, et al. : Fatigue in long-term breast carcinoma survivors. Cancer 106:751-758, 2006
    1. Di Meglio A, Michiels S, Jones LW, et al. : Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study. Breast 52:23-32, 2020
    1. Chlebowski RT, Reeves MM: Weight loss randomized intervention trials in female cancer survivors. J Clin Oncol 34:4238-4248, 2016
    1. Mishra SI, Scherer RW, Snyder C, et al. : Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev 2012:CD008465, 2012
    1. Mishra SI, Scherer RW, Geigle PM, et al. : Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev 2012:CD007566, 2012
    1. Kroenke CH, Chen WY, Rosner B, et al. : Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23:1370-1378, 2005
    1. Irwin ML, Smith AW, McTiernan A, et al. : Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: The health, eating, activity, and lifestyle study. J Clin Oncol 26:3958-3964, 2008
    1. Peppone LJ, Mustian KM, Morrow GR, et al. : The effect of cigarette smoking on cancer treatment–related side effects. Oncologist 16:1784-1792, 2011
    1. Warren GW, Sobus S, Gritz ER: The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. Lancet Oncol 15:e568-e580, 2014
    1. Zhan M, Flaws JA, Gallicchio L, et al. : Profiles of tamoxifen-related side effects by race and smoking status in women with breast cancer. Cancer Detect Prev 31:384-390, 2007
    1. Land SR, Cronin WM, Wickerham DL, et al. : Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the national surgical adjuvant breast and bowel project P-1 breast cancer prevention trial. Cancer Prev Res 4:1393-1400, 2011
    1. Peters EN, Torres E, Toll BA, et al. : Tobacco assessment in actively accruing national cancer Institute cooperative group program clinical trials. J Clin Oncol 30:2869-2875, 2012
    1. Ganz PA: Host factors, behaviors, and clinical trials: Opportunities and challenges. J Clin Oncol 30:2817-2819, 2012
    1. Goodwin SJ, McCarthy CM, Pusic AL, et al. : Complications in smokers after postmastectomy tissue expander/implant breast reconstruction. Ann Plast Surg 55:16-20, 2005
    1. Jang S, Prizment A, Haddad T, et al. : Smoking and quality of life among female survivors of breast, colorectal and endometrial cancers in a prospective cohort study. J Cancer Surviv 5:115-122, 2011
    1. Parada H, Bradshaw PT, Steck SE, et al. : Postdiagnosis changes in cigarette smoking and survival following breast cancer. JNCI Cancer Spectr 1:pkx001, 2017
    1. Passarelli MN, Newcomb PA, Hampton JM, et al. : Cigarette smoking before and after breast cancer diagnosis: Mortality from breast cancer and smoking-related diseases. J Clin Oncol 34:1315-1322, 2016
    1. Balaam S, Bailey TG, Anderson D, et al. : Alcohol and breast cancer: Results from the women's wellness after cancer program randomized controlled trial. Cancer Nurs 45:87-95, 2022
    1. Tipples K, Robinson A: Optimal management of cancer treatment-induced bone loss: Considerations for elderly patients. Drugs Aging 28:867-883, 2011
    1. Husson O, de Rooij BH, Kieffer J, et al. : The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the “real-world”: Results from the population- based PROFILES registry. Oncologist 25:e722-e732, 2020
    1. Vaz-Luis I, Cottu P, Mesleard C, et al. : UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open 4:e000562, 2019
    1. Aaronson NK, Ahmedzai S, Bergman B, et al. : The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
    1. Giesinger JM, Kieffer JM, Fayers PM, et al. : Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol 69:79-88, 2016
    1. Fayers P, Aaronson NK, Bjordal K, et al. : EORTC QLQ-C30 Scoring Manual. Brussels, Belgium, European Organisation for Research and Treatment of Cancer, 2001
    1. Sprangers MA, Groenvold M, Arraras JI, et al. : The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J Clin Oncol 14:2756-2768, 1996
    1. Questionnaires|EORTC—Quality of Life.
    1. Data and Statistics. 2019.
    1. Global Physical Activity Questionnaire Analysis Guide GPAQ Analysis Guide Global Physical Activity Questionnaire (GPAQ) Analysis Guide.
    1. Nagin DS, Odgers CL: Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 6:109-138, 2010
    1. Nagin DS, Jones BL, Passos VL, et al. : Group-based multi-trajectory modeling. Stat Methods Med Res 27:2015-2023, 2018
    1. Nagin DS: Group-Based Modeling of Development. Cambridge, MA, Harvard University Press, 2005
    1. Choi CWJ, Stone RA, Kim KH, et al. : Group-based trajectory modeling of caregiver psychological distress over time. Ann Behav Med 44:73-84, 2012
    1. Nagin DS, Odgers CL: Group-based trajectory modeling (nearly) two decades later. J Quant Criminol 26:445-453, 2010
    1. van Buuren S, Groothuis-Oudshoorn K: mice: Multivariate imputation by chained equations in R. J Stat Softw 45:1-67, 2011
    1. Rubin DB, Wiley J, York N, et al. : Multiple Imputation for Nonresponse in Surveys. Hoboken, NJ, John Wiley & Sons Inc, 1987
    1. Haviland AM, Jones BL, Nagin DS: Group-based trajectory modeling extended to account for nonrandom participant attrition. Sociologic Methods Res 40:367-390, 2011
    1. Giesinger JM, Loth FLC, Aaronson NK, et al. : Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 118:1-8, 2020
    1. Osoba D, Rodrigues G, Myles J, et al. : Interpreting the significance of changes in health- related quality-of-life scores. J Clin Oncol 16:139-144, 1998
    1. Cocks K, King MT, Velikova G, et al. : Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29:89-96, 2011
    1. Jones LW, Eves ND, Scott JM: Bench-to-bedside approaches for personalized exercise therapy in cancer. Am Soc Clin Oncol Ed Book 37:684-694, 2017
    1. Ballard-Barbash R, Hunsberger S, Alciati MH, et al. : Physical activity, weight control, and breast cancer risk and survival: Clinical trial rationale and design considerations. J Natl Cancer Inst 101:630-643, 2009
    1. Goodwin PJ, Ambrosone CB, Hong C-C: Modifiable lifestyle factors and breast cancer outcomes: Current controversies and research recommendations, in Advances in Experimental Medicine and Biology. New York, NY, Springer New York LLC, 2015, pp 177-192
    1. Betof AS, Dewhirst MW, Jones LW: Effects and potential mechanisms of exercise training on cancer progression: A translational perspective. Brain Behav Immun 30:S75-S87, 2013
    1. Ferson M, Edwards A, Lind A, et al. : Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int J Cancer 23:603-609, 1979
    1. Tartter PI, Steinberg B, Barron DM, et al. : The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 122:1264-1268, 1987
    1. Browman GP, Wong G, Hodson I, et al. : Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 328:159-163, 1993
    1. Jones LW, Eves ND, Haykowsky M, et al. : Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol 10:598-605, 2009
    1. Ganz PA, Petersen L, Bower JE, et al. : Impact of adjuvant endocrine therapy on quality of life and symptoms: Observational data over 12 months from the mind-body study. J Clin Oncol 34:816-824, 2016
    1. LoConte NK, Gershenwald JE, Thomson CA, et al. : Lifestyle modifications and policy Implications for primary and secondary cancer prevention: Diet, exercise, sun safety, and alcohol reduction. Am Soc Clin Oncol Ed Book 38:88-100, 2018
    1. Demark-Wahnefried W, Schmitz KH, Alfano CM, et al. : Weight management and physical activity throughout the cancer care continuum. CA Cancer J Clin 68:64-89, 2018
    1. Iyengar NM, Jones LW: Development of exercise as interception therapy for cancer: A review. JAMA Oncol 5:1620-1627, 2019
    1. Gritz ER, Fingeret MC, Vidrine DJ, et al. : Successes and failures of the teachable moment: Smoking cessation in cancer patients. Cancer 106:17-27, 2006
    1. Klosky JL, Tyc VL, Garces-Webb DM, et al. : Emerging issues in smoking among adolescent and adult cancer survivors. Cancer 110:2408-2419, 2007
    1. Speck RM, Courneya KS, Mâsse LC, et al. : An update of controlled physical activity trials in cancer survivors: A systematic review and meta-analysis. J Cancer Surviv 4:87-100, 2010
    1. Sedjo RL, Flatt SW, Byers T, et al. : Impact of a behavioral weight loss intervention on comorbidities in overweight and obese breast cancer survivors. Support Care Cancer 24:3285-3293, 2016
    1. Demark-Wahnefried W, Colditz GA, Rock CL, et al. : Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors. Breast Cancer Res Treat 154:329-337, 2015
    1. Kenzik KM, Demark-Wahnefried W, Ganz PA, et al. : Changes in body mass index and physical activity predict changes in vitality during a weight loss trial in breast cancer survivors. Ann Behav Med 52:999-1009, 2018
    1. Ligibel JA, Barry WT, Alfano C, et al. : Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): Study design. NPJ Breast Cancer 3:37, 2017
    1. Rack B, Andergassen U, Neugebauer J, et al. : The German SUCCESS C study—The first European lifestyle study on breast cancer. Breast Care 5:395-400, 2010
    1. Di Meglio A, Martin E, Crane TE, et al. : A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA study design. Trials 23:193, 2022
    1. Land SR, Toll BA, Moinpour CM, et al. : Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research. Clin Cancer Res 22:1907-1913, 2016
    1. Ell K, Xie B, Wells A, et al. : Economic stress among low-income women with cancer: Effects on quality of life. Cancer 112:616-625, 2008
    1. Graells-Sans A, Serral G, Puigpinós-Riera R: Social inequalities in quality of life in a cohort of women diagnosed with breast cancer in Barcelona (DAMA cohort). Cancer Epidemiol 54:38-47, 2018
    1. Khadanga S, Lakoski SG, Hart V, et al. : Partnership status and socioeconomic factors in relation to health behavior changes after a diagnosis of ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev 25:76-82, 2016
    1. Ferreira ARR, Di Meglio A, Pistilli B, et al. : Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: A prospective patient-reported outcomes analysis. Ann Oncol 30:1784-1795, 2019
    1. Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. : Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol 34:2452-2459, 2016
    1. Pistilli B, Paci A, Ferreira AR, et al. : Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol 38:2762-2772, 2020
    1. Ribi K, Luo W, Bernhard J, et al. : Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol 34:1601-1610, 2016
    1. Davies C, Pan H, Godwin J, et al. : Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816, 2013
    1. Gray RG, Rea D, Handley K, et al. : aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31, 2013. (abstr 5)
    1. Di Meglio A, Havas J, Soldato D, et al. : Development and validation of a predictive model of severe fatigue after breast cancer diagnosis: Toward a personalized framework in survivorship care. J Clin Oncol 40:1111-1123, 2022
    1. Phillips R, Gandhi M, Cheung YB, et al. : Summary scores captured changes in subjects' QoL as measured by the multiple scales of the EORTC QLQ-C30. J Clin Epidemiol 68:895-902, 2015
    1. Sprangers MAG: Disregarding clinical trial-based patient-reported outcomes is unwarranted: Five advances to substantiate the scientific stringency of quality-of-life measurement. Acta Oncol (Madr) 49:155-163, 2010
    1. Sprangers MAG, Schwartz CE: Integrating response shift into health-related quality of life research: A theoretical model. Soc Sci Med 48:1507-1515, 1999
    1. Phillips SM, Alfano CM, Perna FM, et al. : Accelerating translation of physical activity and cancer survivorship research into practice: Recommendations for a more integrated and collaborative approach. Cancer Epidemiol Biomarkers Prev 23:687-699, 2014
    1. Stull VB, Snyder DC, Demark-Wahnefried W: Lifestyle interventions in cancer survivors: Designing programs that meet the needs of this vulnerable and growing population. J Nutr 137:243S-248S, 2007. (suppl 1)

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever